Salesforce
CRM
Broadcom
AVGO
Qualcomm
QCOM
4
Netflix
NFLX
5
Oracle
ORCL
US Stock MarketDetailed Quotes
ICCM Icecure Medical
- 1.148
- +0.028+2.49%
Trading Apr 24 11:38 ET
67.29MMarket Cap-3.83P/E (TTM)
1.160High1.127Low25.55KVolume1.120Open1.120Pre Close29.42KTurnover0.08%Turnover RatioLossP/E (Static)58.62MShares1.66052wk High9.73P/B35.29MFloat Cap0.48052wk Low--Dividend TTM30.74MShs Float16.000Historical High--Div YieldTTM2.98%Amplitude0.480Historical Low1.151Avg Price1Lot Size
Market Insights
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Icecure Medical Stock Forum
Clinical Trial Reveals Revolutionary Breast Cancer Treatment: ProSense Shows 94% Success, Zero Complications
IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation
Tuesday, 22nd April at 8:30 am
Breast cancer cryoablation was a major focus at ECIO 2025 with a dedicated scientific session
Independent studies of ProSense® featured in scientific sessions and abstracts including data from the THERMAC trial stating 95% of patients said they would choose thermal ablation over breast conserving surgery
In-bo...
IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America
Thursday, 27th March at 8:30 am
Expecting FDA decision on marketing authorization for early-stage low risk breast cancer with endocrine therapy
Positive ProSense® results were reported through 33 peer-reviewed journals and medical conferences during 2024
Conference call to be held today at 10:00 am Eastern Time
CAESAREA, Israel, March 27, 2025 /PRNewswire...
Dow Jones· 2 mins ago
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If y...
Breakthrough: New Kidney Cancer Study Shows 89% Success Rate with IceCure's Freezing Technology
IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate
Monday, 24th March at 8:30 am
Interim Data confirm ProSense® cryoablation is highly effective for kidney tumors ≤3 cm and a safe procedure for kidney tumors ≤5 cm in people ineligible for surgery
CAESAREA, Israel, March 24, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Me...
Icecure's Icesecret Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate
FDA Advisory Panel Endorses Revolutionary Breast Cancer Cryoablation System
No comment yet